老年肌少症与非肌少症患者循环炎症标志物差异的系统综述与荟萃分析
结果显示肌少症患者上述炎症标志物均显著更高,但研究总体质量偏低,IL-6存在发表偏倚,需纵向研究控制合并症与感染后明确因果。
要点
- 肌少症老年人CRP、高敏CRP、IL-6、TNF-α水平均显著高于非肌少症者。
- TNF-α组间差异最大(SMD 0.78),但异质性高达92%。
- IL-6在剔除6项研究后组间差异不再显著,提示发表偏倚影响。
核心结论
- 荟萃分析显示肌少症患者较非肌少症老年人存在更高水平的循环炎症标志物。
- 需纵向研究控制已报告的合并症和感染后确立因果关系。
研究设计与样本
- 遵循PRISMA 2020指南,检索PubMed、Cochrane Library、Web of Science和Scopus。
- 异质性通过荟萃回归评估,发表偏倚采用Egger检验和漏斗图评价。
主要发现
- IL-6存在发表偏倚,剔除6项研究后SMD为0.12(95%CI -0.38至0.61),组间差异不显著。
临床怎么用
- 临床评估肌少症老年人时可关注循环炎症标志物水平,但不宜单独用于诊断。
- 解读炎症标志物时需考虑合并症和感染对结果的潜在影响。
局限性
- 纳入研究总体质量被评为低。
- IL-6存在发表偏倚,剔除后组间差异不显著。
- 纳入研究为横断面设计,无法推断因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In this systematic review and meta-analysis, mean differences among high-sensitivity C-reactive protein (CRP), CRP, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), the most common markers used in clinical practice, between older adults with and without sarcopenia based on established consensus were explored. DESIGN: A random-effects model meta-analysis was used to estimate the pooled effects of the included studies (CRD42024503466). Heterogeneity was assessed via meta-regressions, whereas publication bias was evaluated through Egger's test and funnel plots. SETTING AND PARTICIPANTS: Forty-four studies with cross-sectional baseline data were included in this study. METHODS: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, a systematic literature search of studies was conducted using PubMed, Cochrane Library, Web of Science, and Scopus. RESULTS: Sarcopenia exhibited a significant higher inflammatory profile compared with those without sarcopenia (CRP: standardized mean difference [SMD], 0.27; 95% CI, 0.14-0.40; I2 = 82%; P < .01), (high-sensitivity CRP: SMD, 0.40; 95% CI, 0.20-0.60; I2 = 79%; P < .01), (IL-6: SMD, 0.34; 95% CI, 0.12-0.56; I2 = 72%; P < .01), (tumor necrosis factor-alpha: SMD, 0.78; 95% CI, 0.25-1.32; I2 = 92%; P < .01). Overall, the quality of the studies was considered low. Publication bias was found in relation to IL-6, for which, following trim of 6 studies, an insignificant effect between groups was observed (SMD, 0.12; 95% CI, -0.38 to 0.61). CONCLUSIONS AND IMPLICATIONS: This meta-analysis showed a higher level of inflammation in sarcopenia vs nonsarcopenia. Longitudinal studies controlling for reported comorbidities and infections are needed to establish causality.
引用
- Prokopidis K, Exmann CJC, Morwani-Mangnani J, et al. Differences in Circulating Inflammatory Markers in Older Adults With and Without Sarcopenia: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2026. PMID: 42398194. doi:10.1016/j.jamda.2026.106312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。